Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. - Wikidata - wikimedia - TriplyDB

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q43430750

about

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Optimal combination of antiangiogenic therapy for hepatocellular carcinoma PET and MR imaging: the odd couple or a match made in heaven?Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Imaging biomarker roadmap for cancer studies Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice Vascular endothelial growth factor receptor-2 in breast cancer.Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.Anti-VEGF Cancer Therapy in Nephrology Practice Imaging in clinical trials.Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.Cediranib for metastatic alveolar soft part sarcoma Biomarkers of response and resistance to antiangiogenic therapy.Liver cancer: Targeted future options The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.Novel therapeutic strategies for targeting liver cancer stem cells.Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?

P2860

Q26752752-BBBAE944-5E60-43DE-BE78-EB01CD422CC1 Q26799458-8D150463-D727-4479-801C-743157526882 Q26851721-EEB9AE43-249B-4BC6-A4BB-C054895843B1 Q27024235-2802AADF-F3B7-4729-A5DC-A5BE46DAE73D Q27346895-4360D6CA-EF40-416F-9588-74A4E6F7C7C6 Q30242020-94066831-E2DE-4913-82DC-75808C855A39 Q30806067-72421C29-5F03-49CD-9D54-3DDBFA88263C Q33414769-BB1457EB-68EE-4016-8E9B-5E609EFE2584 Q33415009-6D38A93D-7E1A-4E8D-B362-E21F84C67588 Q33598883-49FCF817-48C4-4654-8BA0-9FBA46AFD726 Q33710574-940BB448-B579-4D1B-9A05-5A58ACC25A4A Q33874179-4AC60C95-F0C0-477C-BE70-3C6482B40D7F Q33900712-EC1A4815-DA79-4357-8025-59F216AC28AC Q33912620-623666B6-840B-497A-A71D-F751C3839178 Q33918044-1820388D-196D-442F-A90E-D385800D5D98 Q33926377-449A4FF4-2312-4AC5-AA91-C5B50CFCD482 Q33990834-D598ACFE-5E36-4204-84CD-11A3C95AB5A5 Q34026037-C0990170-1C00-48A1-A65E-EDED75DD7100 Q34105344-2C4875B8-57D3-4D2B-85BC-82AECA009A5F Q34134697-F0C68C83-63D4-4238-BFBC-75D8FDE1A29B Q34152125-E9BBE352-10E7-4B50-90CD-10AAC3479B3A Q34256382-74017F89-4FCF-4A93-A1D0-BD08CDAAE21A Q34272439-DFB34A94-7EDB-49BB-BB0A-40B8AB2AD775 Q34331739-833DEDC6-3DE5-4036-8D18-E1FCEE8F734B Q34354522-EF7E38DC-6E0E-47DD-9259-3FCD7B81A244 Q34488671-973E68F7-C9A3-42B7-93AE-E68D6C2E858E Q34651131-A3990AC7-59B2-4224-8B34-CE1455B289FE Q34673567-23A3EB4D-F352-4593-A540-B953E934B44B Q34695180-E89040DD-E0B6-468A-999B-47001E4CBC64 Q34725749-21AE9CD0-6A6E-450E-9BE6-B5D58337C7C6 Q34854658-C1744A41-B885-4E39-B716-D307A820D5D6 Q34914220-E2800883-E172-4020-A472-B92F520B08EE Q34940971-6B19DC04-CD24-4D71-9F5C-84BFF1A82469 Q35057364-35C0F394-4E0B-4173-B988-B28588D2A53E Q35078518-84041784-FDF2-412D-B648-B55963C4A866 Q35419004-D19AD6F1-368D-4D8E-8055-E4848BC956BC Q35536088-EE21A4FE-FE2A-4673-ADE9-17F666F3EE05 Q35599819-BA478A71-AC43-4FE0-B0FB-76342BB521FB Q35659433-450EB6D1-A4C3-4317-8488-6F6CEBEA8B80 Q35879814-35BBA452-103B-4BB2-8313-B220F559A800

P2860

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q43430750

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@en

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@nl

type

label

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@en

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@nl

prefLabel

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@en

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@nl

P1433

Q43430750-89D04E1F-31B7-47B8-B826-79C2B7CCA84F

P1476

Q43430750-8FC1CBE5-1453-4CC3-AC8A-75D7ACDAD18F

P2093

Q43430750-144EBD4F-7096-45F6-B8D1-7E3C0545D7E5

Q43430750-1FC62C16-41E8-4005-9820-47D7759E1C21

Q43430750-2B642C57-3E54-480C-90D1-67E7B62CBE2B

Q43430750-4EDD57A2-689B-47D1-98BA-E61025433F9A

Q43430750-6B895834-AB55-4BFE-87D2-F9D0C13345B5

Q43430750-7BA7E9D7-4F33-44E3-A404-403E30EC8275

Q43430750-7E147B3E-9332-436E-A426-5E4BC26278AF

Q43430750-8EBE215E-2BC7-47B9-B9F0-A488E84B61B2

Q43430750-B09E082F-064A-484E-8EFA-59C93127EE64

Q43430750-B6B230E5-CAE5-40DB-B38E-DB9BA7121740

P304

Q43430750-BF648F26-23F8-454B-8025-D1C7383C6563

P31

Q43430750-5271214B-558E-4FB0-9A80-1D39FFCF105E

P356

Q43430750-11DDB61F-53E7-4A83-B23C-8D593C3646D2

P407

Q43430750-F8B31D75-BB22-4C36-B0FB-26277C83A9ED

P433

Q43430750-F67A628B-1624-4EDA-9226-0877BEEA0328

P478

Q43430750-07405816-3D30-40C6-9D70-8A1B3386F8E1

P577

Q43430750-CE237F7B-1AF4-477B-A8F6-BEB9A1E5D21A

P698

Q43430750-BB2BA01C-E3FD-45C5-88F7-E34EAC2035E3

P921

Q43430750-8241B9E1-4D44-4E0E-A5BC-5149FEEAD8C4

P356

JCO.2006.07.2066

P1433

Journal of Clinical Oncology

P1476

Phase I clinical study of AZD2 ...... ts with advanced solid tumors.

@en

P2093

Clemens Unger

http://www.w3.org/2001/XMLSchema#string

Helen Young

http://www.w3.org/2001/XMLSchema#string

Hubert Blum

http://www.w3.org/2001/XMLSchema#string

Jan Harder

http://www.w3.org/2001/XMLSchema#string

Jane Robertson

http://www.w3.org/2001/XMLSchema#string

Joachim Drevs

http://www.w3.org/2001/XMLSchema#string

Juliane M Jürgensmeier

http://www.w3.org/2001/XMLSchema#string

Klaus Mross

http://www.w3.org/2001/XMLSchema#string

Michael Medinger

http://www.w3.org/2001/XMLSchema#string

Owain Saunders

http://www.w3.org/2001/XMLSchema#string

P304

3045-3054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.07.2066

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17634482

http://www.w3.org/2001/XMLSchema#string

P921